Fig 1.
Study design, follow-up and analysis of participant datasets in the form of a CONSORT flow diagram.
Table 1.
Optimization of BoNT-A parameters over the study treatment course for PD participants.
Table 2.
Optimization of BoNT-A parameters over the study treatment course for ET participants.
Fig 2.
Significant effect of serial kinematically-based BoNT-A treatments on reducing tremor severity and functional disability caused by tremor and QoL improvements by validated clinical scales and kinematic tremor analysis along the whole-arm.
(a-b) Mean UPDRS item 20 and 21 in the treated and untreated limbs in PD and ET participants; (c) Mean FTM part A-C scores in PD participants; (d) Mean FTM part A-C scores in ET participants; Mean angular RMS tremor amplitudes at the wrist in (e) PD participants and in (f) ET participants; (g) Mean QUEST score in ET participants; (h) mean Likert scale scores in PD and ET participants; (i) Percentage of participants who scored ≤3 on the MMT scale for finger flexion and extension, and (j) Mean maximal grip strength scores in the treated limb in both participant groups. Asterisks indicate statistical significance in means compared to week 0 and the asterisk colours are coordinated with each line plot (*). Injections were administered every 16 weeks starting at week 0.
Table 3.
Optimization of BoNT-A parameters over the study treatment course for PD participants.
Table 4.
Optimization of BoNT-A parameters over the study treatment course for ET participants.